STERIS (STE)
Supplies sterilization equipment, procedural products, and services for healthcare and life-sciences workflows.
Something off on this page? Send us feedback.
Serves healthcare providers and life-sciences manufacturers with sterilization equipment, procedural products, consumables, maintenance, repair, reprocessing, and contract microbial-reduction services. Healthcare generates most revenue, supported by global Applied Sterilization Technologies and Life Sciences operations.
Supplies hospitals and procedure centers with sterilizers, surgical tables, endoscope reprocessors, consumables, instruments, operating-room connectivity, equipment maintenance, and outsourced instrument reprocessing. Healthcare is the largest segment and generates most revenue; although the business serves customers worldwide, most revenue comes from the United States.
Applied Sterilization Technologies operates a global network that sterilizes medical devices and pharmaceuticals, performs laboratory testing, and supplies integrated sterilization equipment and process controls. Life Sciences provides washers, sterilizers, cleanroom chemistries, water systems, decontamination systems, and maintenance for aseptic manufacturing.
Combines capital equipment with consumables, installation, repair, and outsourced processing across regulated workflows. Operations depend on procedure volumes, regulated product and facility approvals, and access to ethylene oxide and cobalt-60 for contract sterilization.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $275 |
| May 21, 2026 | Piper Sandler | Target | Target: $260 | Target: $270 |
| May 13, 2026 | Keybanc | Reiterate | Rating: —Target: $265 | Target: $269 |
| Jul 15, 2025 | Morgan Stanley | Upgrade | ||
| Oct 24, 2024 | Piper Sandler | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $482.3M · Total debt $2.04B · Total assets $10.74B · Shareholders' equity $7.21B
- Revenue
- $1.49B
- Operating income
- $285.8M
- Net income
- $200.1M
HistoryDividendAnnual yield
| Institutions | 97.84% | 95.50M shares | |
|---|---|---|---|
| 844 holders · as of Jun 30, 2026 | |||
| Insiders | 0.29% | 286.7K shares | |
| 13 holders · as of Aug 12, 2026 | |||
| Other | 1.87% | 1.82M shares | |
| remainder | |||
97.60M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.04% | 8.82M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.56% | 6.41M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.20% | 5.07M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.12% | 5.00M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 4.05% | 3.95M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Mohsen Sohi | director | −4,058 | $235.78 |
| Jun 15, 2026 | John Adam Zangerle | officer: Sr. VP, Gen Counsel, and Sec. | −1,419 | $209.28 |
| Jun 5, 2026 | Daniel A. Carestio | director, officer: President and CEO | −1,374 | $212.00 |
| Jun 4, 2026 | Daniel A. Carestio | director, officer: President and CEO | −3,054 | $214.64 |
| Jun 2, 2026 | Richard C. Breeden | director | −1,481 | $209.51 |
- Sotera Health
Direct AST peer in contract sterilization and lab testing
- Fortive
ASP challenges low-temperature sterilization and reprocessing
- Ecolab
Competes in infection-prevention chemistry and contamination control
- Solventum
Targets sterility assurance and surgical infection prevention
- Stryker
Adjacent rival in surgical instruments and OR workflow
- Boston Scientific
Narrow GI endoscopy rival with infection-prevention products
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| STERIS | $207.92 | +0.46% | $20.17B | 25.3 | 18.1 | 3.3 | +7.1% |
| Sotera Health | $18.83 | +0.69% | $5.33B | 32.7 | 18.3 | 4.4 | +9.2% |
| Fortive | $55.78 | +1.26% | $16.64B | 32.4 | 17.9 | 3.9 | −27.8% |
| Ecolab | $274.60 | +1.71% | $75.98B | 36.2 | 31.8 | 4.5 | +9.7% |
| Solventum | $89.05 | +0.24% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| Stryker | $276.38 | +0.80% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Boston Scientific | $44.75 | +2.34% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Median | 30.4 | 17.6 | 4.0 | +8.4% |